| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/12/2013 | CA2475310C Antimicrobial streptococcus salivarius strain and use thereof for preventing dental caries |
| 02/12/2013 | CA2468892C Vitamin d analogues |
| 02/12/2013 | CA2462646C Adjuvanted meningococcus compositions |
| 02/12/2013 | CA2445634C Acne treatment comprising lipoxygenase inhibitors |
| 02/12/2013 | CA2429817C Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 02/12/2013 | CA2419529C Diagnosis and treatment of tumor-suppressor associated disorders |
| 02/12/2013 | CA2388450C Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 02/10/2013 | CA2784853A1 Solid pharmaceutical compound for oral administration of agomelatine |
| 02/10/2013 | CA2755715A1 Antihypertensive agents |
| 02/07/2013 | WO2013020108A2 Bile acid recycling inhibitors for treatment of pancreatitis |
| 02/07/2013 | WO2013020097A1 Double-stranded oligonucleotide compounds for treating hearing and balance disorders |
| 02/07/2013 | WO2013020074A2 A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
| 02/07/2013 | WO2013020069A1 Treatment of type 2 diabetes with fty720 |
| 02/07/2013 | WO2013020062A1 Quinazoline compounds as serine/threonine kinase inhibitors |
| 02/07/2013 | WO2013020044A1 Treatment of fibrosis using microrna-19b |
| 02/07/2013 | WO2013020024A2 Maleimide compounds and methods of treatment |
| 02/07/2013 | WO2013020017A1 Trans-clomiphene metabolites and uses thereof |
| 02/07/2013 | WO2013020014A1 Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
| 02/07/2013 | WO2013019980A1 Compositions and methods for the treatment of asthma and associated disorders |
| 02/07/2013 | WO2013019974A1 Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea |
| 02/07/2013 | WO2013019967A1 Modulators of virus assembly as antiviral agents |
| 02/07/2013 | WO2013019966A1 Aromatic bycyclic derivatives as cxcr4 receptor modulators |
| 02/07/2013 | WO2013019945A2 Method for selection of chemotherapeutic agents for adenocarcinoma cancer |
| 02/07/2013 | WO2013019938A1 Pyridazine derivatives as eaat2 activators |
| 02/07/2013 | WO2013019932A1 Methods for treating immunosuppression |
| 02/07/2013 | WO2013019926A1 Treatment and prevention of diseases mediated by microorganisms via drug-mediated manipulation of the eicosanoid balance |
| 02/07/2013 | WO2013019917A2 Permanent attachment of ammonium and guanidine-based antimicrobials to surfaces containing c-h functionality |
| 02/07/2013 | WO2013019908A1 Subcutaneous needle assisted jet injection administration of methotrexate |
| 02/07/2013 | WO2013019901A2 Tropinol esters and related compounds to promote normal processing of app |
| 02/07/2013 | WO2013019874A1 Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates |
| 02/07/2013 | WO2013019872A1 Process for preparing pharmaceutical compositions comprising fingolimod |
| 02/07/2013 | WO2013019857A2 Method for improving the success rate of hematopoietic stem cell transplants |
| 02/07/2013 | WO2013019828A1 Inhibitors of influenza viruses replication |
| 02/07/2013 | WO2013019745A1 Methods and compositions for genetically modifiying cells |
| 02/07/2013 | WO2013019733A2 Methods, compositions and kits for therapeutic treatment with wet spun microstructures |
| 02/07/2013 | WO2013019731A2 Phosphate prodrugs |
| 02/07/2013 | WO2013019690A1 Small molecule inhibitors of il-6 and uses thereof |
| 02/07/2013 | WO2013019682A1 Compounds and methods |
| 02/07/2013 | WO2013019662A1 Aryl naphthalide lignans as anti-hiv agents |
| 02/07/2013 | WO2013019658A2 Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
| 02/07/2013 | WO2013019653A1 Compounds and methods |
| 02/07/2013 | WO2013019635A1 Compounds and methods |
| 02/07/2013 | WO2013019626A1 Compounds and methods |
| 02/07/2013 | WO2013019623A2 Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
| 02/07/2013 | WO2013019621A1 Compounds and methods |
| 02/07/2013 | WO2013019620A2 Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody |
| 02/07/2013 | WO2013019561A1 Nuclear transport modulators and uses thereof |
| 02/07/2013 | WO2013019548A1 Hydrazide containing nuclear transport modulators and uses thereof |
| 02/07/2013 | WO2013019280A1 Corticosteroids for the treatment of joint pain |
| 02/07/2013 | WO2013019271A1 Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters |
| 02/07/2013 | WO2013019221A1 Compositions and methods for treating myelodysplastic syndrome |
| 02/07/2013 | WO2013019220A1 Compositions and methods for treating myelodysplastic syndrome |
| 02/07/2013 | WO2013019169A1 Phosphate prodrugs |
| 02/07/2013 | WO2013019163A1 Paraffin in therapy and as a cosmetic preparation |
| 02/07/2013 | WO2013019156A1 3-hydroxyanthranilic acid (3-haa) therapy for prevention and treatment of hyperlipidemia and its cardiovascular complications |
| 02/07/2013 | WO2013019093A2 Novel aniline derivatives and use thereof |
| 02/07/2013 | WO2013019091A2 A COMPOUND FOR INHIBITING 11β-HYDROXY STEROID DEHYDROGENASE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| 02/07/2013 | WO2013019079A2 Composition containing 5-hydroxyindole compounds or sponge scalarispongia sp. extracts as active ingredients for prevention and treatment of cancer diseases |
| 02/07/2013 | WO2013019058A2 Pharmaceutical composition for inhibiting cancer recurrence or metastasis |
| 02/07/2013 | WO2013019056A1 Novel granule formulation containing sildenafil or pharmaceutically acceptable salts thereof as an active ingredient |
| 02/07/2013 | WO2013018929A1 Nitrogen-containing heterocyclic compound |
| 02/07/2013 | WO2013018899A1 Dibenzooxepin derivative |
| 02/07/2013 | WO2013018879A1 Protein exhibiting fatty acid elongation promoting activity, gene encoding same and use thereof |
| 02/07/2013 | WO2013018837A1 Left ventricular diastolic function improving agent |
| 02/07/2013 | WO2013018829A1 Method for treating cancer by combined use of medicinal agents |
| 02/07/2013 | WO2013018804A1 Uracil derivative and use thereof for medical purposes |
| 02/07/2013 | WO2013018779A1 CRYSTAL OF α-GLUCOSYL HESPERIDIN AND USE THEREOF |
| 02/07/2013 | WO2013018766A1 Stable pharmaceutical composition |
| 02/07/2013 | WO2013018765A1 Pharmaceutical composition containing loxoprofen |
| 02/07/2013 | WO2013018759A1 Anti-adhesion medical material and method for producing same |
| 02/07/2013 | WO2013018735A1 Amidine compound or salt thereof |
| 02/07/2013 | WO2013018733A1 1,5-naphthyridine derivative or salt thereof |
| 02/07/2013 | WO2013018706A1 Composition for regulating urat1 activity |
| 02/07/2013 | WO2013018695A1 Heterocyclic compound |
| 02/07/2013 | WO2013018685A1 Lactam derivative and use thereof for medical purposes |
| 02/07/2013 | WO2013018675A1 N-hetero-ring-substituted amide derivative |
| 02/07/2013 | WO2013018374A1 Ketone derivative and drug containing same |
| 02/07/2013 | WO2013018372A1 Amide derivative and drug containing same |
| 02/07/2013 | WO2013018371A1 Biaryl ester derivative and drug containing same |
| 02/07/2013 | WO2013018362A1 2-acylaminothiazole compound crystals |
| 02/07/2013 | WO2013018100A1 A process for the preparation of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide crystalline form i |
| 02/07/2013 | WO2013018096A1 Use of integrase for targeted gene expression |
| 02/07/2013 | WO2013018095A1 Compounds and compositions for use in augmentation of glucose uptake and insulin secretion |
| 02/07/2013 | WO2013018091A1 Particles for the treatment of neurodegenerative diseases |
| 02/07/2013 | WO2013018069A1 Combination of antimalarial agents |
| 02/07/2013 | WO2013018060A2 Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
| 02/07/2013 | WO2013018031A1 Pharmaceutical compositions for gastrointestinal drug delivery |
| 02/07/2013 | WO2013018018A1 Antitumour combination comprising ombrabulin and cetuximab, associated with radiotherapy |
| 02/07/2013 | WO2013018017A1 Antitumour combination comprising ombrabulin and cisplatin, associated with radiotherapy |
| 02/07/2013 | WO2013018008A1 Basic alpha lipoic acid solution and its uses |
| 02/07/2013 | WO2013017989A1 Crizotinib for use in the treatment of cancer |
| 02/07/2013 | WO2013017977A1 Compositions and methods for the treatment of cancer |
| 02/07/2013 | WO2013017974A1 Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
| 02/07/2013 | WO2013017910A1 Extended release pharmaceutical compositions containing paliperidone |
| 02/07/2013 | WO2013017821A1 Pharmaceutical composition comprising ebastine and fluticasone |
| 02/07/2013 | WO2013017808A1 Antiseptic composition |
| 02/07/2013 | WO2013017807A1 Antiseptic composition |
| 02/07/2013 | WO2013017724A1 Use of a combination of azathioprine and l-buthionine-[s,r]-sulfoximine in the preparation of a drug useful in the treatment of a refractory tumor |
| 02/07/2013 | WO2013017678A1 Novel spiroindoline compounds |
| 02/07/2013 | WO2013017657A1 Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |